{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Esther Wollert",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer’s Disease",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "PUBCHEM": "^\\d+$",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"
    },
    "path": "app/morsy2018.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "03cefaaf8169d67f15ee5c84682c3de8",
      "line": 91,
      "relation": "increases",
      "source": 11,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "9c210df205e69dc2d0b8c4b4419642c9",
      "line": 97,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 11,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "3672c777bc6ba6f36e07d275e6ce09d2",
      "line": 92,
      "relation": "increases",
      "source": 7,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "af12594581a519a30cb55eb382d6bec7",
      "line": 98,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 7,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "e399831c5b8d474ec899e1fbd1d192e1",
      "line": 93,
      "relation": "increases",
      "source": 10,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "9f72fac16080e0772cc250858f831d99",
      "line": 99,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 10,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "149361abd20f6476e38c33a027c0c907",
      "line": 94,
      "relation": "increases",
      "source": 8,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "a8b4b6c1eeb068c331d6bfabdfd5964f",
      "line": 100,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 8,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "bc16135a9c935440309b1afc5e31fc1c",
      "line": 95,
      "relation": "increases",
      "source": 9,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Only five drugs (Figure 1) have been approved by the U. S. Food and Drug Administration (FDA), four of which are cholinesterase inhibitors (tacrine, 15  donepezil, 16  rivastigmine 17  and galantamine 18 ) and one of which is a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). a N-methyl-D-aspartate (NMDA) receptor antagonist (memantine 19 ). These pharmacological agents have  had  limited  effect  in  improving  the  cognitive  function  of  AD  patients  and  do  not  slow  the progression of the disease. Clinical studies have shown that these agents temporarily stabilize cognitive impairment and help to maintain global function, delaying the need for patient palliative care by only a few month",
      "key": "c952d1e0ee6671306a1c084086ca63b3",
      "line": 101,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 9,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Genetics have a role to play within AD; patients with a mutation in Amyloid Precursor Protein (APP), which results in overproduction of Aβ, will experience early onset AD. 36  Patients with a mutation in Apolipoprotein E4 (APOE4), which affects the clearance of Aβ, will experience late onset AD.",
      "key": "3d35cc5dd78efbb450da513cfb82d067",
      "line": 108,
      "relation": "increases",
      "source": 46,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Genetics have a role to play within AD; patients with a mutation in Amyloid Precursor Protein (APP), which results in overproduction of Aβ, will experience early onset AD. 36  Patients with a mutation in Apolipoprotein E4 (APOE4), which affects the clearance of Aβ, will experience late onset AD.",
      "key": "d9957591ed3a31edded2bfc59a99d048",
      "line": 109,
      "relation": "increases",
      "source": 46,
      "target": 30
    },
    {
      "key": "c26ac6b2e0088f81fabe5b43c4fa266b",
      "relation": "hasVariant",
      "source": 45,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Binding of Aβ to ABAD has been implicated in the development of AD, recent studies detected elevated ABAD levels in the regions of the hippocampus and cerebral cortex which are generally affected by AD pathology",
      "key": "0856ce8aa3da4d7b48bb36906a8e31d4",
      "line": 150,
      "relation": "positiveCorrelation",
      "source": 79,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The first, peroxiredoxin-2 (Prdx-2), functions as an antioxidant and has been shown to  be inactivated  in  AD.",
      "key": "a446de1eed1f85420455e73fbe30db80",
      "line": 278,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 79,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true,
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "In  transgenic  AD  mice  and  the  post-mortem  human  brain  of  AD patients, the expression of Prdx-2 is shown to be elevated, due to the attempted protection of neurons from Aβ-induced toxicity.",
      "key": "1e87fc4c023867140b7311230eb2de0e",
      "line": 286,
      "relation": "positiveCorrelation",
      "source": 79,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Inactivation of Prdx-2 is controlled by a kinase that has been shown to be elevated in AD, CDK5, 107, 108  which phosphorylates Thr 89  and results in deactivation of Prdx-2.",
      "key": "33a41ef8ea0612bc671447d1d34f1fe6",
      "line": 293,
      "relation": "positiveCorrelation",
      "source": 79,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The second ABAD-related protein, endophilin-1 (Ep-1), is a member of a family of proteins that are responsible for synaptic vesicle endocytosis, mitochondrial function, and receptor trafficking. 110  This family of proteins has been implicated in a number of neurodegenerative diseases, 111  including in AD where it is overexpressed",
      "key": "095bd2fbf103d400bda8119cbaefce09",
      "line": 305,
      "relation": "positiveCorrelation",
      "source": 79,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Genetics have a role to play within AD; patients with a mutation in Amyloid Precursor Protein (APP), which results in overproduction of Aβ, will experience early onset AD. 36  Patients with a mutation in Apolipoprotein E4 (APOE4), which affects the clearance of Aβ, will experience late onset AD.",
      "key": "9984c1efa345a63f1c7a67eaba98b72f",
      "line": 110,
      "relation": "increases",
      "source": 44,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Genetics have a role to play within AD; patients with a mutation in Amyloid Precursor Protein (APP), which results in overproduction of Aβ, will experience early onset AD. 36  Patients with a mutation in Apolipoprotein E4 (APOE4), which affects the clearance of Aβ, will experience late onset AD.",
      "key": "6ab28bab886aa21b3bab96a696716f12",
      "line": 111,
      "relation": "increases",
      "source": 44,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " In addition, several other gene mutations have been discovered such as Presenilin-1 and Presenilin-2 mutations, which increase the risk for developing AD. 38  ",
      "key": "16d17ce0eb17f4cd333a7fa281eaa014",
      "line": 118,
      "relation": "increases",
      "source": 48,
      "target": 79
    },
    {
      "key": "8366b5fccdf2874d4f6b0c95b0cd1a88",
      "relation": "hasVariant",
      "source": 47,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " In addition, several other gene mutations have been discovered such as Presenilin-1 and Presenilin-2 mutations, which increase the risk for developing AD. 38  ",
      "key": "aa520681241a98d33d31357cbb0c0788",
      "line": 119,
      "relation": "increases",
      "source": 50,
      "target": 79
    },
    {
      "key": "32d348762538e6043fab44f8bad602e4",
      "relation": "hasVariant",
      "source": 49,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The formation of Aβ starts by a transmembrane protein, APP (695 to 770 amino acids in length), which is sequentially cleaved by the aspartate proteases β- and  γ-secretase,  that  leads  to  the  formation  of  Aβ  peptide  (1-42)  and  a  degenerated  C-terminus. ",
      "key": "1565332faa8efad7662ccbbc7a406b3b",
      "line": 127,
      "relation": "increases",
      "source": 57,
      "target": 84
    },
    {
      "key": "0e962ae4c3cc70b712fabbae560ec836",
      "relation": "hasReactant",
      "source": 84,
      "target": 56
    },
    {
      "key": "fbce08374e5a34b538a82fe7dcacc233",
      "relation": "hasProduct",
      "source": 84,
      "target": 2
    },
    {
      "key": "f734eaec0f1293fcf83092a4e6ba8a34",
      "relation": "hasProduct",
      "source": 84,
      "target": 51
    },
    {
      "key": "b1a4954aef40d3888f3dc9523962cef1",
      "relation": "partOf",
      "source": 56,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The formation of Aβ starts by a transmembrane protein, APP (695 to 770 amino acids in length), which is sequentially cleaved by the aspartate proteases β- and  γ-secretase,  that  leads  to  the  formation  of  Aβ  peptide  (1-42)  and  a  degenerated  C-terminus. ",
      "key": "a7e9e728d7d55c6c4d7342353f066f4d",
      "line": 128,
      "relation": "increases",
      "source": 52,
      "target": 84
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Mitochondrial  dysfunction  is  the  hallmark  of  Aβ-induced toxicity. 50-52  ",
      "key": "4d5cdcbd6d5a5fea43ef82f4581c2bc9",
      "line": 134,
      "relation": "increases",
      "source": 13,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Accumulation of Aβ has also been associated with a decrease in the activity of cytochrome c oxidase, the terminal enzyme in the electron transport chain. ",
      "key": "15f162fb4cfeb39fa4fa03d65f4f0ffa",
      "line": 140,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 13,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Binding of Aβ to ABAD has been implicated in the development of AD, recent studies detected elevated ABAD levels in the regions of the hippocampus and cerebral cortex which are generally affected by AD pathology",
      "key": "bb9671ba34b7a2061af37244d7ace04e",
      "line": 148,
      "relation": "increases",
      "source": 42,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Neurons from these animals exhibited increased oxidative stress, increased generation of ROS, DNA fragmentation, neuronal apoptosis, and impairment in learning, compared to single-transgenic mAPP mice.",
      "key": "227db538409507b3e5215b44e90d7eae",
      "line": 221,
      "relation": "increases",
      "source": 42,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Neurons from these animals exhibited increased oxidative stress, increased generation of ROS, DNA fragmentation, neuronal apoptosis, and impairment in learning, compared to single-transgenic mAPP mice.",
      "key": "49317aca0041f2141460e98fcd8f071b",
      "line": 222,
      "relation": "increases",
      "source": 42,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "In another study, neurons from Tg mAPP/ABAD mice were shown to exhibit decreased activity of cyclooxygenase (COX) enzyme, spontaneous release of ROS, loss of mitochondrial membrane potential, a decrease in ATP production and release of cytochrome c from mitochondria with subsequent induction of caspase-3-like activity followed by apoptotic cell death.",
      "key": "571eec62db4e0ace33ed45be0732a159",
      "line": 237,
      "relation": "increases",
      "source": 42,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Neurons from these animals exhibited increased oxidative stress, increased generation of ROS, DNA fragmentation, neuronal apoptosis, and impairment in learning, compared to single-transgenic mAPP mice.",
      "key": "8b502ecce024edd966885c7278ed1ec6",
      "line": 223,
      "relation": "increases",
      "source": 42,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Neurons from these animals exhibited increased oxidative stress, increased generation of ROS, DNA fragmentation, neuronal apoptosis, and impairment in learning, compared to single-transgenic mAPP mice.",
      "key": "6244ad4c5ddf15ee73d6351c574af206",
      "line": 224,
      "relation": "increases",
      "source": 42,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Neurons from these animals exhibited increased oxidative stress, increased generation of ROS, DNA fragmentation, neuronal apoptosis, and impairment in learning, compared to single-transgenic mAPP mice.",
      "key": "627dc0d0ba5c418f367c73bcb2cc7a06",
      "line": 225,
      "relation": "decreases",
      "source": 42,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "In another study, neurons from Tg mAPP/ABAD mice were shown to exhibit decreased activity of cyclooxygenase (COX) enzyme, spontaneous release of ROS, loss of mitochondrial membrane potential, a decrease in ATP production and release of cytochrome c from mitochondria with subsequent induction of caspase-3-like activity followed by apoptotic cell death.",
      "key": "6836d2abc377145d0ce2eb4345a8be20",
      "line": 236,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 42,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "In another study, neurons from Tg mAPP/ABAD mice were shown to exhibit decreased activity of cyclooxygenase (COX) enzyme, spontaneous release of ROS, loss of mitochondrial membrane potential, a decrease in ATP production and release of cytochrome c from mitochondria with subsequent induction of caspase-3-like activity followed by apoptotic cell death.",
      "key": "a98d4f134b419529a6736c224d1a2d5d",
      "line": 238,
      "relation": "decreases",
      "source": 42,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "In another study, neurons from Tg mAPP/ABAD mice were shown to exhibit decreased activity of cyclooxygenase (COX) enzyme, spontaneous release of ROS, loss of mitochondrial membrane potential, a decrease in ATP production and release of cytochrome c from mitochondria with subsequent induction of caspase-3-like activity followed by apoptotic cell death.",
      "key": "f602c1e78098affe8dc5fa1c8a5e7db1",
      "line": 239,
      "relation": "decreases",
      "source": 42,
      "target": 5
    },
    {
      "annotations": {
        "CellStructure": {
          "Mitochondria": true
        },
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "In another study, neurons from Tg mAPP/ABAD mice were shown to exhibit decreased activity of cyclooxygenase (COX) enzyme, spontaneous release of ROS, loss of mitochondrial membrane potential, a decrease in ATP production and release of cytochrome c from mitochondria with subsequent induction of caspase-3-like activity followed by apoptotic cell death.",
      "key": "29edc154f33669b6329840af19a972bf",
      "line": 241,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 42,
      "target": 19
    },
    {
      "annotations": {
        "CellStructure": {
          "Mitochondria": true
        },
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "In another study, neurons from Tg mAPP/ABAD mice were shown to exhibit decreased activity of cyclooxygenase (COX) enzyme, spontaneous release of ROS, loss of mitochondrial membrane potential, a decrease in ATP production and release of cytochrome c from mitochondria with subsequent induction of caspase-3-like activity followed by apoptotic cell death.",
      "key": "78b212e6430db52fc349c908adc019ef",
      "line": 242,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 42,
      "target": 61
    },
    {
      "annotations": {
        "CellStructure": {
          "Mitochondria": true
        },
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "In another study, neurons from Tg mAPP/ABAD mice were shown to exhibit decreased activity of cyclooxygenase (COX) enzyme, spontaneous release of ROS, loss of mitochondrial membrane potential, a decrease in ATP production and release of cytochrome c from mitochondria with subsequent induction of caspase-3-like activity followed by apoptotic cell death.",
      "key": "5ca7aeae254843da61c3b3357c4154d1",
      "line": 243,
      "relation": "increases",
      "source": 42,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "However, it is well established that Aβ binding to ABAD induces a conformational change in the enzyme that  prevents  the  binding  of  NAD + ,  preventing  the  enzyme  performing  its  role  in  the  oxidation  of substrates, leading to changes in mitochondrial membrane permeability, which in turn has deleterious effects  on  mitochondrial  enzymes.",
      "key": "da817bd365083fe27a23cf9d11e169e9",
      "line": 252,
      "relation": "decreases",
      "source": 42,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "However, it is well established that Aβ binding to ABAD induces a conformational change in the enzyme that  prevents  the  binding  of  NAD + ,  preventing  the  enzyme  performing  its  role  in  the  oxidation  of substrates, leading to changes in mitochondrial membrane permeability, which in turn has deleterious effects  on  mitochondrial  enzymes.",
      "key": "262e406f3449941ae2eaff1155978aae",
      "line": 253,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 42,
      "target": 66
    },
    {
      "key": "7c832e47497ce6ecb09e3e4cfb00f553",
      "relation": "partOf",
      "source": 66,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Binding of Aβ to ABAD has been implicated in the development of AD, recent studies detected elevated ABAD levels in the regions of the hippocampus and cerebral cortex which are generally affected by AD pathology",
      "key": "221f1bbaae307c220e875062c500a599",
      "line": 150,
      "relation": "positiveCorrelation",
      "source": 66,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The  enzyme  is  also  required  for  the catabolism of isoleucine, in which it catalyzes the conversion of 2-methyl-3-hydroxybutyryl-coA (MHB) to 2-methyl-acetoacetyl-coA. 72  ",
      "key": "7d3db7136ca9315545aeb76b03418b67",
      "line": 159,
      "relation": "increases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 82
    },
    {
      "annotations": {
        "CellStructure": {
          "Mitochondria": true
        },
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The enzyme catalyzes the third step of mitochondrial oxidation, converting  L -3-hydroxyacyl-CoA in the presence of NAD +  to 3-ketoacyl-CoA, NADH, and H + .",
      "key": "499fe8894002fab831f5f21015ac1fc8",
      "line": 166,
      "relation": "increases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The  oxidation  of  3-adiol  to  5-dihydrotestosterone  in androgen  metabolism  is  catalyzed  by  ABAD  and  it  converts  17β-estradiol  to  estrone  in  estrogen metabolism.",
      "key": "0866e2471a233a64ca41fc7b97712dfa",
      "line": 175,
      "relation": "increases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 81
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The  oxidation  of  3-adiol  to  5-dihydrotestosterone  in androgen  metabolism  is  catalyzed  by  ABAD  and  it  converts  17β-estradiol  to  estrone  in  estrogen metabolism.",
      "key": "1058fc4c0f405d512b2dd64c6dc28b7f",
      "line": 176,
      "relation": "increases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  function  of  ABAD  has  also  been  associated  with  GABA A   receptors,  as  it  catalyzes  the oxidation of the neurosteroids allopregnanolone and allotetrahydrodeoxycorticosterone, both of which are positive modulators of GABA A  receptors in the brain.",
      "key": "b4f4396a45851302bf25f3b1e59248ec",
      "line": 183,
      "relation": "association",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 76
    },
    {
      "key": "d7cf45e5fedc2d2033fc9636dabf85c7",
      "relation": "partOf",
      "source": 66,
      "target": 41
    },
    {
      "key": "8a5b17e725e6b18eb963c7c6502c31f9",
      "relation": "hasReactant",
      "source": 82,
      "target": 23
    },
    {
      "key": "e79fb8d9c81daf45b8d30e7202c6e347",
      "relation": "hasProduct",
      "source": 82,
      "target": 20
    },
    {
      "key": "1aa74a9fa4a2bc093ba7d89ebb1efdaf",
      "relation": "hasReactant",
      "source": 80,
      "target": 1
    },
    {
      "key": "cbb01819e2319eec0f00db426c6e8574",
      "relation": "hasReactant",
      "source": 80,
      "target": 27
    },
    {
      "key": "9a0343f6ba05d97ab111cd2952c36082",
      "relation": "hasProduct",
      "source": 80,
      "target": 0
    },
    {
      "key": "8e4e64f0f0bf25bb2132f3178be23307",
      "relation": "hasProduct",
      "source": 80,
      "target": 6
    },
    {
      "key": "02a69b29e8d0c1e164e1443650953f83",
      "relation": "hasProduct",
      "source": 80,
      "target": 16
    },
    {
      "key": "d79d8a13f345fe167ce858f018f27306",
      "relation": "partOf",
      "source": 1,
      "target": 41
    },
    {
      "key": "93b9a409986dc99da13735f0829eb52e",
      "relation": "hasReactant",
      "source": 81,
      "target": 18
    },
    {
      "key": "ae5eb795bf0124415e09f89fcbfd0cc7",
      "relation": "hasProduct",
      "source": 81,
      "target": 17
    },
    {
      "key": "7d96634b6330a6367e83cac7f9c3d647",
      "relation": "hasReactant",
      "source": 83,
      "target": 24
    },
    {
      "key": "c00f6d6a8bec994cec9da02f685390df",
      "relation": "hasProduct",
      "source": 83,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " For example, estradiol can reduce the generation of Aβ by altering the metabolism of APP and disrupting it’s trafficking.",
      "key": "246f1cf76646a179beba1c8b8be9fc5e",
      "line": 191,
      "relation": "decreases",
      "source": 24,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  estradiol  has  been  shown  to  inhibit  tau  hyperphosphorylation  and  can  also  modulate glycogen  synthase  kinase-3β  (GSK-3β)  activity,  a  kinase  that  is  involved  in  tau  phosphorylation. Estradiol  deactivates  GSK-3β  by  inducing  its  phosphorylation,  thereafter  reducing  tau phosphorylation. ",
      "key": "4a5720d91cb4c48b99dd1a36e4fce0e0",
      "line": 199,
      "relation": "decreases",
      "source": 24,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  estradiol  has  been  shown  to  inhibit  tau  hyperphosphorylation  and  can  also  modulate glycogen  synthase  kinase-3β  (GSK-3β)  activity,  a  kinase  that  is  involved  in  tau  phosphorylation. Estradiol  deactivates  GSK-3β  by  inducing  its  phosphorylation,  thereafter  reducing  tau phosphorylation. ",
      "key": "85e2e0ba88d04920ced0812f79c9934e",
      "line": 200,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 24,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  estradiol  has  been  shown  to  inhibit  tau  hyperphosphorylation  and  can  also  modulate glycogen  synthase  kinase-3β  (GSK-3β)  activity,  a  kinase  that  is  involved  in  tau  phosphorylation. Estradiol  deactivates  GSK-3β  by  inducing  its  phosphorylation,  thereafter  reducing  tau phosphorylation. ",
      "key": "b78410c4aec1bb1260f18c6ef275abf4",
      "line": 201,
      "relation": "increases",
      "source": 24,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "  It  enhances  the  expression  of  anti- apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulates the expression of Bim, a pro-apoptotic factor, preventing programmed cell death. 90, 100  Estradiol also activates antioxidant systems to protect neuronal cells from apoptosis by upregulating the expression of manganese superoxide dismutase and glutathione peroxidase. 101  ",
      "key": "33d603358684c884ab1f4e7892fbb697",
      "line": 265,
      "relation": "increases",
      "source": 24,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "  It  enhances  the  expression  of  anti- apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulates the expression of Bim, a pro-apoptotic factor, preventing programmed cell death. 90, 100  Estradiol also activates antioxidant systems to protect neuronal cells from apoptosis by upregulating the expression of manganese superoxide dismutase and glutathione peroxidase. 101  ",
      "key": "98c9fa2ea567e4031bdb08169261f21f",
      "line": 266,
      "relation": "increases",
      "source": 24,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "  It  enhances  the  expression  of  anti- apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulates the expression of Bim, a pro-apoptotic factor, preventing programmed cell death. 90, 100  Estradiol also activates antioxidant systems to protect neuronal cells from apoptosis by upregulating the expression of manganese superoxide dismutase and glutathione peroxidase. 101  ",
      "key": "08aeba543fade5127fb86d712db69f6a",
      "line": 267,
      "relation": "decreases",
      "source": 24,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "  It  enhances  the  expression  of  anti- apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulates the expression of Bim, a pro-apoptotic factor, preventing programmed cell death. 90, 100  Estradiol also activates antioxidant systems to protect neuronal cells from apoptosis by upregulating the expression of manganese superoxide dismutase and glutathione peroxidase. 101  ",
      "key": "eed71754413b93cc6d5d090bdd34a739",
      "line": 271,
      "relation": "increases",
      "source": 24,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "  It  enhances  the  expression  of  anti- apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulates the expression of Bim, a pro-apoptotic factor, preventing programmed cell death. 90, 100  Estradiol also activates antioxidant systems to protect neuronal cells from apoptosis by upregulating the expression of manganese superoxide dismutase and glutathione peroxidase. 101  ",
      "key": "15271e72c45f013775ce0e9d2c0a8af4",
      "line": 272,
      "relation": "increases",
      "source": 24,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  function  of  ABAD  has  also  been  associated  with  GABA A   receptors,  as  it  catalyzes  the oxidation of the neurosteroids allopregnanolone and allotetrahydrodeoxycorticosterone, both of which are positive modulators of GABA A  receptors in the brain.",
      "key": "6ed69f1c3036123ea3058c69fb3529af",
      "line": 183,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 76,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  function  of  ABAD  has  also  been  associated  with  GABA A   receptors,  as  it  catalyzes  the oxidation of the neurosteroids allopregnanolone and allotetrahydrodeoxycorticosterone, both of which are positive modulators of GABA A  receptors in the brain.",
      "key": "c194ab313744ed4223da8cb48c9ca00f",
      "line": 184,
      "relation": "positiveCorrelation",
      "source": 76,
      "subject": {
        "modifier": "Activity"
      },
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  function  of  ABAD  has  also  been  associated  with  GABA A   receptors,  as  it  catalyzes  the oxidation of the neurosteroids allopregnanolone and allotetrahydrodeoxycorticosterone, both of which are positive modulators of GABA A  receptors in the brain.",
      "key": "d8dcfab10f225d541d5410c8b360ff58",
      "line": 185,
      "relation": "positiveCorrelation",
      "source": 76,
      "subject": {
        "modifier": "Activity"
      },
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  function  of  ABAD  has  also  been  associated  with  GABA A   receptors,  as  it  catalyzes  the oxidation of the neurosteroids allopregnanolone and allotetrahydrodeoxycorticosterone, both of which are positive modulators of GABA A  receptors in the brain.",
      "key": "95f058d35d702e003cbf966585aba345",
      "line": 184,
      "object": {
        "modifier": "Activity"
      },
      "relation": "positiveCorrelation",
      "source": 15,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  function  of  ABAD  has  also  been  associated  with  GABA A   receptors,  as  it  catalyzes  the oxidation of the neurosteroids allopregnanolone and allotetrahydrodeoxycorticosterone, both of which are positive modulators of GABA A  receptors in the brain.",
      "key": "3beb8948817c73179dad6256fe9df221",
      "line": 185,
      "object": {
        "modifier": "Activity"
      },
      "relation": "positiveCorrelation",
      "source": 26,
      "target": 76
    },
    {
      "key": "b5ef526ab5a17da51fd96bb875e02aac",
      "relation": "hasVariant",
      "source": 69,
      "target": 70
    },
    {
      "key": "064f60bbd4e86ec0d71e89e733af2e71",
      "relation": "hasVariant",
      "source": 69,
      "target": 71
    },
    {
      "key": "cf26414172b4f2dbd1cd7e2820e6bbb3",
      "relation": "hasVariant",
      "source": 64,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Moreover,  estradiol  has  been  shown  to  inhibit  tau  hyperphosphorylation  and  can  also  modulate glycogen  synthase  kinase-3β  (GSK-3β)  activity,  a  kinase  that  is  involved  in  tau  phosphorylation. Estradiol  deactivates  GSK-3β  by  inducing  its  phosphorylation,  thereafter  reducing  tau phosphorylation. ",
      "key": "b4562b4d8b7273de90b57dad212e1478",
      "line": 202,
      "relation": "increases",
      "source": 64,
      "subject": {
        "modifier": "Activity"
      },
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " In mechanistic studies, it was proposed that methylene blue inhibits the Aβ-ABAD interaction and decreases mitochondrial dysfunction by decreasing the expression of ABAD levels, in addition to decreasing Aβ levels.",
      "key": "897522dacb08bd94df9fd464bb10bff6",
      "line": 209,
      "relation": "decreases",
      "source": 3,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " In mechanistic studies, it was proposed that methylene blue inhibits the Aβ-ABAD interaction and decreases mitochondrial dysfunction by decreasing the expression of ABAD levels, in addition to decreasing Aβ levels.",
      "key": "d8d2512f9f83f27e979faf6309d143bc",
      "line": 210,
      "relation": "decreases",
      "source": 3,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " In mechanistic studies, it was proposed that methylene blue inhibits the Aβ-ABAD interaction and decreases mitochondrial dysfunction by decreasing the expression of ABAD levels, in addition to decreasing Aβ levels.",
      "key": "2889764cde1e65412c9c9ef5e1820496",
      "line": 211,
      "relation": "decreases",
      "source": 3,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " In mechanistic studies, it was proposed that methylene blue inhibits the Aβ-ABAD interaction and decreases mitochondrial dysfunction by decreasing the expression of ABAD levels, in addition to decreasing Aβ levels.",
      "key": "d322535fc0c78978009589123fb69f46",
      "line": 212,
      "relation": "decreases",
      "source": 3,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " This results in the activation of mitogen-activated protein kinase kinase kinase 1 (MAP3K1), 114  which then activates a cascade of kinases that eventually leads to the translocation of JNK to the nucleus or other target sites to phosphorylate downstream effectors,  thereby  affecting  significant  aspects  of  neuronal  function  such  as  neurite  outgrowth, mitochondrial  function,  synaptic  plasticity  and  apoptosis. 1",
      "key": "18f3eedfc815a06ed4713852ce84fe52",
      "line": 319,
      "relation": "association",
      "source": 33,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "  It  enhances  the  expression  of  anti- apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulates the expression of Bim, a pro-apoptotic factor, preventing programmed cell death. 90, 100  Estradiol also activates antioxidant systems to protect neuronal cells from apoptosis by upregulating the expression of manganese superoxide dismutase and glutathione peroxidase. 101  ",
      "key": "bae7b7955fe05efb0597599e67f36e42",
      "line": 268,
      "relation": "decreases",
      "source": 58,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "  It  enhances  the  expression  of  anti- apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulates the expression of Bim, a pro-apoptotic factor, preventing programmed cell death. 90, 100  Estradiol also activates antioxidant systems to protect neuronal cells from apoptosis by upregulating the expression of manganese superoxide dismutase and glutathione peroxidase. 101  ",
      "key": "47d1c1445e57d1c9b8e7803fa7e580f1",
      "line": 269,
      "relation": "decreases",
      "source": 59,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "  It  enhances  the  expression  of  anti- apoptotic proteins, such as Bcl-2 and Bcl-xL, and down-regulates the expression of Bim, a pro-apoptotic factor, preventing programmed cell death. 90, 100  Estradiol also activates antioxidant systems to protect neuronal cells from apoptosis by upregulating the expression of manganese superoxide dismutase and glutathione peroxidase. 101  ",
      "key": "07a168c63070aba571f88198c4d6911a",
      "line": 270,
      "relation": "increases",
      "source": 60,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The first, peroxiredoxin-2 (Prdx-2), functions as an antioxidant and has been shown to  be inactivated  in  AD.",
      "key": "a3423740ee6e67fe6740e36ea08a0c6e",
      "line": 278,
      "relation": "negativeCorrelation",
      "source": 72,
      "subject": {
        "modifier": "Activity"
      },
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "Species": {
          "10090": true,
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "In  transgenic  AD  mice  and  the  post-mortem  human  brain  of  AD patients, the expression of Prdx-2 is shown to be elevated, due to the attempted protection of neurons from Aβ-induced toxicity.",
      "key": "9dc4071988da1e1a71a67012026b10b4",
      "line": 286,
      "relation": "positiveCorrelation",
      "source": 72,
      "target": 79
    },
    {
      "key": "ed24eb6e07918aa01ee68015ec1fdab9",
      "relation": "hasVariant",
      "source": 72,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Inactivation of Prdx-2 is controlled by a kinase that has been shown to be elevated in AD, CDK5, 107, 108  which phosphorylates Thr 89  and results in deactivation of Prdx-2.",
      "key": "4f75eb7027981b8e383d83f335668cd3",
      "line": 293,
      "relation": "positiveCorrelation",
      "source": 62,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Inactivation of Prdx-2 is controlled by a kinase that has been shown to be elevated in AD, CDK5, 107, 108  which phosphorylates Thr 89  and results in deactivation of Prdx-2.",
      "key": "5f19c99a82576b81bf2cd37a34a34953",
      "line": 294,
      "relation": "increases",
      "source": 62,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Inactivation of Prdx-2 is controlled by a kinase that has been shown to be elevated in AD, CDK5, 107, 108  which phosphorylates Thr 89  and results in deactivation of Prdx-2.",
      "key": "b947ecaa74d3431b6b86a0a4cdaaa04e",
      "line": 295,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 73,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The second ABAD-related protein, endophilin-1 (Ep-1), is a member of a family of proteins that are responsible for synaptic vesicle endocytosis, mitochondrial function, and receptor trafficking. 110  This family of proteins has been implicated in a number of neurodegenerative diseases, 111  including in AD where it is overexpressed",
      "key": "a275eee7bb1c3096918d450e80e789d5",
      "line": 304,
      "relation": "increases",
      "source": 74,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The second ABAD-related protein, endophilin-1 (Ep-1), is a member of a family of proteins that are responsible for synaptic vesicle endocytosis, mitochondrial function, and receptor trafficking. 110  This family of proteins has been implicated in a number of neurodegenerative diseases, 111  including in AD where it is overexpressed",
      "key": "5f0658dc518c02c6f1ba2f053b2a99df",
      "line": 305,
      "relation": "positiveCorrelation",
      "source": 74,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " This results in the activation of mitogen-activated protein kinase kinase kinase 1 (MAP3K1), 114  which then activates a cascade of kinases that eventually leads to the translocation of JNK to the nucleus or other target sites to phosphorylate downstream effectors,  thereby  affecting  significant  aspects  of  neuronal  function  such  as  neurite  outgrowth, mitochondrial  function,  synaptic  plasticity  and  apoptosis. 1",
      "key": "33212dc3df5a62863a938346602a3f31",
      "line": 315,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 74,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " This results in the activation of mitogen-activated protein kinase kinase kinase 1 (MAP3K1), 114  which then activates a cascade of kinases that eventually leads to the translocation of JNK to the nucleus or other target sites to phosphorylate downstream effectors,  thereby  affecting  significant  aspects  of  neuronal  function  such  as  neurite  outgrowth, mitochondrial  function,  synaptic  plasticity  and  apoptosis. 1",
      "key": "4c37ea12b636953b228c9e1dcdc94188",
      "line": 317,
      "relation": "association",
      "source": 74,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " This results in the activation of mitogen-activated protein kinase kinase kinase 1 (MAP3K1), 114  which then activates a cascade of kinases that eventually leads to the translocation of JNK to the nucleus or other target sites to phosphorylate downstream effectors,  thereby  affecting  significant  aspects  of  neuronal  function  such  as  neurite  outgrowth, mitochondrial  function,  synaptic  plasticity  and  apoptosis. 1",
      "key": "cfa709cdd54b5af436f132e4e916f486",
      "line": 318,
      "relation": "association",
      "source": 74,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " This results in the activation of mitogen-activated protein kinase kinase kinase 1 (MAP3K1), 114  which then activates a cascade of kinases that eventually leads to the translocation of JNK to the nucleus or other target sites to phosphorylate downstream effectors,  thereby  affecting  significant  aspects  of  neuronal  function  such  as  neurite  outgrowth, mitochondrial  function,  synaptic  plasticity  and  apoptosis. 1",
      "key": "5803eead5fee4364002456f45333a46f",
      "line": 319,
      "relation": "association",
      "source": 74,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " This results in the activation of mitogen-activated protein kinase kinase kinase 1 (MAP3K1), 114  which then activates a cascade of kinases that eventually leads to the translocation of JNK to the nucleus or other target sites to phosphorylate downstream effectors,  thereby  affecting  significant  aspects  of  neuronal  function  such  as  neurite  outgrowth, mitochondrial  function,  synaptic  plasticity  and  apoptosis. 1",
      "key": "52d7e4a990757ba9d0816363c1108acb",
      "line": 316,
      "relation": "increases",
      "source": 68,
      "subject": {
        "modifier": "Activity"
      },
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " This results in the activation of mitogen-activated protein kinase kinase kinase 1 (MAP3K1), 114  which then activates a cascade of kinases that eventually leads to the translocation of JNK to the nucleus or other target sites to phosphorylate downstream effectors,  thereby  affecting  significant  aspects  of  neuronal  function  such  as  neurite  outgrowth, mitochondrial  function,  synaptic  plasticity  and  apoptosis. 1",
      "key": "045605ad47a226e760629e89c5b0035d",
      "line": 317,
      "relation": "association",
      "source": 34,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " This results in the activation of mitogen-activated protein kinase kinase kinase 1 (MAP3K1), 114  which then activates a cascade of kinases that eventually leads to the translocation of JNK to the nucleus or other target sites to phosphorylate downstream effectors,  thereby  affecting  significant  aspects  of  neuronal  function  such  as  neurite  outgrowth, mitochondrial  function,  synaptic  plasticity  and  apoptosis. 1",
      "key": "3fcff8ccfdd8ffd19a9791ddc526c35f",
      "line": 318,
      "relation": "association",
      "source": 36,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "A potent ABAD inhibitor, AG18051 (1), containing a pyrazolo[3,4-d] pyrimidine-4(1H)-thione backbone (IC 50  = 92 nM) has been reported. ",
      "key": "e70bc93bf5e6651b663bf8c28b9707d4",
      "line": 328,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 14,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Moreover, it has been shown to ameliorate Aβ-induced toxicity at the cellular level. 7",
      "key": "75e00152c6478d6d4ea54f57036a3b1d",
      "line": 335,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 14,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Interestingly, during the search for inhibitors of 17β-HSD isoforms for the treatment of estrogen- related diseases, 127  Ayan et.al identified the steroidal compound RM-532-46 (8) as a reversible ABAD inhibitor (IC 50  = 0.55 M).",
      "key": "8380c1991a41f2517d1d54a235ada6d8",
      "line": 343,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 12,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Frentizole,  an  FDA  approved  immunosuppressant  drug,  was  identified  as  an  Aβ-ABAD interaction  inhibitor  (IC 50  =  200  M)  using  an  ELISA-based  screening  assay.",
      "key": "28291366422d298fdb2e9bc1644d16f6",
      "line": 349,
      "relation": "decreases",
      "source": 22,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "Screening previously synthesized frentizole derivatives for their efficiency to inhibit CK1 activity as well as ABAD, identified compound 13 which possessed an ABAD IC 50  = 1.67 µM, the most  potent  inhibitor  of  this  chemotype  identified  to  date.",
      "key": "38965755b4ca36103dc7e75a657d2342",
      "line": 365,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 22,
      "target": 63
    },
    {
      "key": "fdada92207548b86b22cedc7abcce790",
      "relation": "partOf",
      "source": 22,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Isoforms  of  CK1  are  responsible  for  tau phosphorylation. 129   The  enzyme  can  modulate  the  activity  of  γ-secretase  and  consequently  the production of Aβ.",
      "key": "d8fcc829963d2f6828bdf4f4b0a7b4c6",
      "line": 356,
      "relation": "increases",
      "source": 63,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Isoforms  of  CK1  are  responsible  for  tau phosphorylation. 129   The  enzyme  can  modulate  the  activity  of  γ-secretase  and  consequently  the production of Aβ.",
      "key": "39a314dec2065edc356eece5bb3e2fd1",
      "line": 357,
      "object": {
        "modifier": "Activity"
      },
      "relation": "regulates",
      "source": 63,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": " Isoforms  of  CK1  are  responsible  for  tau phosphorylation. 129   The  enzyme  can  modulate  the  activity  of  γ-secretase  and  consequently  the production of Aβ.",
      "key": "7930e1f5ceb644d6de8cdd5e2c680d11",
      "line": 358,
      "relation": "increases",
      "source": 63,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Morsy A",
          "Trippier PC"
        ],
        "date": "2019-05-09",
        "db": "PubMed",
        "db_id": "30444369",
        "db_name": "Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.",
        "first": "Morsy A",
        "journal": "Journal of medicinal chemistry",
        "last": "Trippier PC",
        "pages": "4252-4264",
        "volume": "62"
      },
      "evidence": "The frentizole scaffold has been combined with the known monoamine oxidase inhibitor (MAOI) ladostigil to identify a molecule that has a dual effect; inhibiting both ABAD and MAO. A library of synthesized derivatives demonstrated that the most potent inhibitor for MAO (IC 50  = 6.34 µM) lacked ABAD inhibition activity.",
      "key": "cda8e5e64a3edfe234146e13fa82e56d",
      "line": 373,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 43,
      "target": 67
    },
    {
      "key": "3b2713a517b940a12eb3a5634be4326d",
      "relation": "partOf",
      "source": 21,
      "target": 43
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"3-oxo-fatty acyl-CoA(4-)\")",
      "concept": {
        "name": "3-oxo-fatty acyl-CoA(4-)",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7d1d669e2c64bab94da60ac8d4158796"
    },
    {
      "bel": "a(CHEBI:\"NAD(+)\")",
      "concept": {
        "name": "NAD(+)",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "50eaf93a4d7570611fd5a5567613b000"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta polypeptide 42\")",
      "concept": {
        "name": "amyloid-beta polypeptide 42",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "ef705fbb8d4e7ba18fb04daf5d329b6b"
    },
    {
      "bel": "a(CHEBI:\"methylene blue\")",
      "concept": {
        "name": "methylene blue",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7beb4cf796511846dabed14b6118ee48"
    },
    {
      "bel": "a(CHEBI:\"reactive oxygen species\")",
      "concept": {
        "name": "reactive oxygen species",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "39a67bec2ea8cb7a2bec39cf66e565ba"
    },
    {
      "bel": "a(CHEBI:ATP)",
      "concept": {
        "name": "ATP",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "08c2bd47cf55782389bbaba34887a39c"
    },
    {
      "bel": "a(CHEBI:NADH)",
      "concept": {
        "name": "NADH",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "514389c8e929fc525b5f01a83ee17920"
    },
    {
      "bel": "a(CHEBI:donepezil)",
      "concept": {
        "name": "donepezil",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "09a116b652169bb3a6e79d234f74875d"
    },
    {
      "bel": "a(CHEBI:galanthamine)",
      "concept": {
        "name": "galanthamine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e801888eadb6e8f7cdcbdafe3172ef65"
    },
    {
      "bel": "a(CHEBI:memantine)",
      "concept": {
        "name": "memantine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "fbc9887dc54845a22697f68a954e7a69"
    },
    {
      "bel": "a(CHEBI:rivastigmine)",
      "concept": {
        "name": "rivastigmine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "cba4a9d79d3c1fd998126a3b26bbe752"
    },
    {
      "bel": "a(CHEBI:tacrine)",
      "concept": {
        "name": "tacrine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "5690926d17521cb6baad2615643644d2"
    },
    {
      "bel": "a(CONSO:\"RM-532-46\")",
      "concept": {
        "name": "RM-532-46",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "3b5a30b025755d095378fdb0cd43a9c0"
    },
    {
      "bel": "a(CONSO:\"amyloid-beta aggregates\")",
      "concept": {
        "name": "amyloid-beta aggregates",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "cb9ddfdb593aa8073305b79828d71376"
    },
    {
      "bel": "a(CONSO:AG18051)",
      "concept": {
        "name": "AG18051",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "8b8d6cfb7ea1fc7d7e74086a5ee7497e"
    },
    {
      "bel": "a(PUBCHEM:101790)",
      "concept": {
        "name": "101790",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "1645b564ce100e1173bdba238bc48adb"
    },
    {
      "bel": "a(PUBCHEM:1038)",
      "concept": {
        "name": "1038",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "57927624989327cd7dbd11ee4e4e9090"
    },
    {
      "bel": "a(PUBCHEM:10635)",
      "concept": {
        "name": "10635",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "31d4506d69ff7dfdcb2343c65878e5ad"
    },
    {
      "bel": "a(PUBCHEM:15818)",
      "concept": {
        "name": "15818",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "ce310d19d4edb482dcef7cd79e344f2e"
    },
    {
      "bel": "a(PUBCHEM:16057918)",
      "concept": {
        "name": "16057918",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "fe12d2c46d856892f2ef135e89937b2c"
    },
    {
      "bel": "a(PUBCHEM:193425)",
      "concept": {
        "name": "193425",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "b00cfc4202bd420cf05d048c9444a04b"
    },
    {
      "bel": "a(PUBCHEM:208907)",
      "concept": {
        "name": "208907",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "3421507a1d0b26dbaa050661cf79bc6f"
    },
    {
      "bel": "a(PUBCHEM:33334)",
      "concept": {
        "name": "33334",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "4ebd14c41248cfc34e4ca009af708a59"
    },
    {
      "bel": "a(PUBCHEM:440326)",
      "concept": {
        "name": "440326",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "99b57d3e0d25fe8cfad710c975510db4"
    },
    {
      "bel": "a(PUBCHEM:5757)",
      "concept": {
        "name": "5757",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "fd3d4b235730b966e67ab14d361be517"
    },
    {
      "bel": "a(PUBCHEM:5870)",
      "concept": {
        "name": "5870",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "2770521bb78cf3f05f4e73ec06db7d10"
    },
    {
      "bel": "a(PUBCHEM:92786)",
      "concept": {
        "name": "92786",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "c5e5a9092e35c510fe9894c36f5a0d29"
    },
    {
      "bel": "a(PUBCHEM:9543037)",
      "concept": {
        "name": "9543037",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "ca16df071dcf28707023510f459163dc"
    },
    {
      "bel": "bp(GO:\"JNK cascade\")",
      "concept": {
        "name": "JNK cascade",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "550e14251b28246bec04ce81dfce7e50"
    },
    {
      "bel": "bp(GO:\"amyloid-beta clearance\")",
      "concept": {
        "name": "amyloid-beta clearance",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "217206493a384413375e9235c66f8344"
    },
    {
      "bel": "bp(GO:\"amyloid-beta formation\")",
      "concept": {
        "name": "amyloid-beta formation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "713c488dcbed512f910b0ccc4167e1e5"
    },
    {
      "bel": "bp(GO:\"apoptotic DNA fragmentation\")",
      "concept": {
        "name": "apoptotic DNA fragmentation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "0acedea259943a42a6a32e8d9fd0ee7a"
    },
    {
      "bel": "bp(GO:\"apoptotic process\")",
      "concept": {
        "name": "apoptotic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "9eb8739869ef0e82697f61a33d3d6afa"
    },
    {
      "bel": "bp(GO:\"neuron death\")",
      "concept": {
        "name": "neuron death",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "5af039c1f3120f7215931236c3c03804"
    },
    {
      "bel": "bp(GO:\"neuron projection development\")",
      "concept": {
        "name": "neuron projection development",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "b7f19b107f0a29154ed6a83a68686b99"
    },
    {
      "bel": "bp(GO:\"regulation of mitochondrial membrane potential\")",
      "concept": {
        "name": "regulation of mitochondrial membrane potential",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d7179b8852a71e16ec74af33168df335"
    },
    {
      "bel": "bp(GO:\"regulation of synaptic plasticity\")",
      "concept": {
        "name": "regulation of synaptic plasticity",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "03639a6f8b863bc0519adc6ebb4bab7d"
    },
    {
      "bel": "bp(GO:\"response to oxidative stress\")",
      "concept": {
        "name": "response to oxidative stress",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d501b05a4babb0401c86b84d8abf2db7"
    },
    {
      "bel": "bp(GO:\"synaptic vesicle endocytosis\")",
      "concept": {
        "name": "synaptic vesicle endocytosis",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "dea77617fd8b6f0635c1ed2aedc280ca"
    },
    {
      "bel": "bp(GO:cognition)",
      "concept": {
        "name": "cognition",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "24220ec2073c35bcd945681ee9c6ea38"
    },
    {
      "bel": "bp(GO:learning)",
      "concept": {
        "name": "learning",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "75fc4f4e732353b87f83a4a8174ffb29"
    },
    {
      "bel": "complex(a(CHEBI:\"NAD(+)\"), p(HGNC:HSD17B10))",
      "function": "Complex",
      "id": "bd4b16eb62ce8ba1cb26a7b8824f4a9d",
      "members": [
        {
          "bel": "a(CHEBI:\"NAD(+)\")",
          "concept": {
            "name": "NAD(+)",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "50eaf93a4d7570611fd5a5567613b000"
        },
        {
          "bel": "p(HGNC:HSD17B10)",
          "concept": {
            "name": "HSD17B10",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "1d82aae64ebfd231949e4181b5e18d95"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:APP), p(HGNC:HSD17B10))",
      "function": "Complex",
      "id": "3001629a9f3a8d1d483e7d2b4c50c04a",
      "members": [
        {
          "bel": "p(HGNC:APP)",
          "concept": {
            "name": "APP",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d43ae551265c6b6a27038d0b036848cf"
        },
        {
          "bel": "p(HGNC:HSD17B10)",
          "concept": {
            "name": "HSD17B10",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "1d82aae64ebfd231949e4181b5e18d95"
        }
      ]
    },
    {
      "bel": "composite(a(PUBCHEM:208907), a(PUBCHEM:33334))",
      "function": "Composite",
      "id": "46d25e60fbd4c2e0972d4086f035dc12",
      "members": [
        {
          "bel": "a(PUBCHEM:208907)",
          "concept": {
            "name": "208907",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "3421507a1d0b26dbaa050661cf79bc6f"
        },
        {
          "bel": "a(PUBCHEM:33334)",
          "concept": {
            "name": "33334",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "4ebd14c41248cfc34e4ca009af708a59"
        }
      ]
    },
    {
      "bel": "g(CONSO:\"APOE e4\")",
      "concept": {
        "name": "APOE e4",
        "namespace": "CONSO"
      },
      "function": "Gene",
      "id": "a2483d5c80d7b5b3f6695d158215b84b"
    },
    {
      "bel": "g(HGNC:APP)",
      "concept": {
        "name": "APP",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "07bfb6a4d8848e0b6508b5117276aa8c"
    },
    {
      "bel": "g(HGNC:APP, var(\"?\"))",
      "concept": {
        "name": "APP",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "0492aeca62dd861fba5c71f4e754d8df",
      "variants": [
        {
          "hgvs": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "g(HGNC:PSEN1)",
      "concept": {
        "name": "PSEN1",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "ac3ba1216f5c63a9d3ce7d9dbac01097"
    },
    {
      "bel": "g(HGNC:PSEN1, var(\"?\"))",
      "concept": {
        "name": "PSEN1",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "2ba03d302ba26dc7123ca9a60791d313",
      "variants": [
        {
          "hgvs": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "g(HGNC:PSEN2)",
      "concept": {
        "name": "PSEN2",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "ce4833998ad061514c37c9b5881bd549"
    },
    {
      "bel": "g(HGNC:PSEN2, var(\"?\"))",
      "concept": {
        "name": "PSEN2",
        "namespace": "HGNC"
      },
      "function": "Gene",
      "id": "63e6f5412d6c2d9c2a434c0d1e24295a",
      "variants": [
        {
          "hgvs": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(CONSO:\"APP C-terminally truncated carboxyl-terminal fragments\")",
      "concept": {
        "name": "APP C-terminally truncated carboxyl-terminal fragments",
        "namespace": "CONSO"
      },
      "function": "Protein",
      "id": "e74c619edc3731c06f4ce8315ab08668"
    },
    {
      "bel": "p(FPLX:\"Gamma_secretase\")",
      "concept": {
        "name": "Gamma_secretase",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "e5aa42b4d5a7992fe30ecc5d01ae8dd8"
    },
    {
      "bel": "p(FPLX:COX)",
      "concept": {
        "name": "COX",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "fc0190eed1ffd1557e56bd5eb251577c"
    },
    {
      "bel": "p(FPLX:Cholinesterase)",
      "concept": {
        "name": "Cholinesterase",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "d743c713e97c6479feb4d5f0a4d85cb0"
    },
    {
      "bel": "p(FPLX:GPX)",
      "concept": {
        "name": "GPX",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "de912320cc21c6da0eb4a75e11277c92"
    },
    {
      "bel": "p(HGNC:APP)",
      "concept": {
        "name": "APP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d43ae551265c6b6a27038d0b036848cf"
    },
    {
      "bel": "p(HGNC:BACE1)",
      "concept": {
        "name": "BACE1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "334dd03e9a5f223f13995e497b1c156e"
    },
    {
      "bel": "p(HGNC:BCL2)",
      "concept": {
        "name": "BCL2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "fc778e9de9f9cebd455edd38ebaf2874"
    },
    {
      "bel": "p(HGNC:BCL2L1)",
      "concept": {
        "name": "BCL2L1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "b94bede953f804ef5bc22e201c5e5fa4"
    },
    {
      "bel": "p(HGNC:BCL2L11)",
      "concept": {
        "name": "BCL2L11",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0b0e68a8cb35a9554edd2aabcd38c800"
    },
    {
      "bel": "p(HGNC:CASP3)",
      "concept": {
        "name": "CASP3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "bdb963bb3852568b08002cd7bd9187b1"
    },
    {
      "bel": "p(HGNC:CDK5)",
      "concept": {
        "name": "CDK5",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cb1e1b28f1d3fe30db837d601f26fe1b"
    },
    {
      "bel": "p(HGNC:CSNK1A1)",
      "concept": {
        "name": "CSNK1A1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8c21303d909c4a8a8e0ce82cada0683b"
    },
    {
      "bel": "p(HGNC:GSK3B)",
      "concept": {
        "name": "GSK3B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8eaf29c9e491ff4e49619e77de92467c"
    },
    {
      "bel": "p(HGNC:GSK3B, pmod(Ph))",
      "concept": {
        "name": "GSK3B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "dde2bce5abacd48b29eb5a38a1c7ccbc",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:HSD17B10)",
      "concept": {
        "name": "HSD17B10",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1d82aae64ebfd231949e4181b5e18d95"
    },
    {
      "bel": "p(HGNC:MAOA)",
      "concept": {
        "name": "MAOA",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5029c077246947b75b7e33319b6d0e29"
    },
    {
      "bel": "p(HGNC:MAP3K1)",
      "concept": {
        "name": "MAP3K1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c5f3b727932ef934be999625d00726d9"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(CONSO:hyperphosphorylation))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0d2d8072f03dcdf148e658067d37b9cb",
      "variants": [
        {
          "concept": {
            "name": "hyperphosphorylation",
            "namespace": "CONSO"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a8fb3a87d5a0672c07462bb17c8b0947",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:PRDX2)",
      "concept": {
        "name": "PRDX2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "0071e197b0e37e38b3a80f85675e859a"
    },
    {
      "bel": "p(HGNC:PRDX2, pmod(Ph, Thr, 89))",
      "concept": {
        "name": "PRDX2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "09075d58a209a79604c4172eed89b9c4",
      "variants": [
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 89
        }
      ]
    },
    {
      "bel": "p(HGNC:SH3GL2)",
      "concept": {
        "name": "SH3GL2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ece506b00f032740f768d58af48373ec"
    },
    {
      "bel": "p(HGNC:SOD2)",
      "concept": {
        "name": "SOD2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c90b5598e3e1682946b933498612a84d"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Gamma-aminobutyric acid type A receptor subunits\")",
      "concept": {
        "name": "Gamma-aminobutyric acid type A receptor subunits",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "07bbf38fb5fa8dd67c15def36559a21d"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Glutamate ionotropic receptor NMDA type subunits\")",
      "concept": {
        "name": "Glutamate ionotropic receptor NMDA type subunits",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "b7afccdb6102ed56132b102ce2e5f6e6"
    },
    {
      "bel": "path(CONSO:\"mitochondrial dysfunction\")",
      "concept": {
        "name": "mitochondrial dysfunction",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "14a330b2e354b7af4f380b05664a5728"
    },
    {
      "bel": "path(MESH:\"Alzheimer Disease\")",
      "concept": {
        "name": "Alzheimer Disease",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2ae8307f5fd59056199369691367cc96"
    },
    {
      "bel": "rxn(reactants(a(CHEBI:\"NAD(+)\"), a(PUBCHEM:9543037)), products(a(CHEBI:\"3-oxo-fatty acyl-CoA(4-)\"), a(CHEBI:NADH), a(PUBCHEM:1038)))",
      "function": "Reaction",
      "id": "c4e16ee210852f58ec8600f11426a888",
      "products": [
        {
          "bel": "a(CHEBI:\"3-oxo-fatty acyl-CoA(4-)\")",
          "concept": {
            "name": "3-oxo-fatty acyl-CoA(4-)",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "7d1d669e2c64bab94da60ac8d4158796"
        },
        {
          "bel": "a(CHEBI:NADH)",
          "concept": {
            "name": "NADH",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "514389c8e929fc525b5f01a83ee17920"
        },
        {
          "bel": "a(PUBCHEM:1038)",
          "concept": {
            "name": "1038",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "57927624989327cd7dbd11ee4e4e9090"
        }
      ],
      "reactants": [
        {
          "bel": "a(CHEBI:\"NAD(+)\")",
          "concept": {
            "name": "NAD(+)",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "50eaf93a4d7570611fd5a5567613b000"
        },
        {
          "bel": "a(PUBCHEM:9543037)",
          "concept": {
            "name": "9543037",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "ca16df071dcf28707023510f459163dc"
        }
      ]
    },
    {
      "bel": "rxn(reactants(a(PUBCHEM:15818)), products(a(PUBCHEM:10635)))",
      "function": "Reaction",
      "id": "0ee0e5adde01a495ec001f1d43d94d5b",
      "products": [
        {
          "bel": "a(PUBCHEM:10635)",
          "concept": {
            "name": "10635",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "31d4506d69ff7dfdcb2343c65878e5ad"
        }
      ],
      "reactants": [
        {
          "bel": "a(PUBCHEM:15818)",
          "concept": {
            "name": "15818",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "ce310d19d4edb482dcef7cd79e344f2e"
        }
      ]
    },
    {
      "bel": "rxn(reactants(a(PUBCHEM:440326)), products(a(PUBCHEM:193425)))",
      "function": "Reaction",
      "id": "6a92267b6ea37acfe2757b671d53f9d2",
      "products": [
        {
          "bel": "a(PUBCHEM:193425)",
          "concept": {
            "name": "193425",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "b00cfc4202bd420cf05d048c9444a04b"
        }
      ],
      "reactants": [
        {
          "bel": "a(PUBCHEM:440326)",
          "concept": {
            "name": "440326",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "99b57d3e0d25fe8cfad710c975510db4"
        }
      ]
    },
    {
      "bel": "rxn(reactants(a(PUBCHEM:5757)), products(a(PUBCHEM:5870)))",
      "function": "Reaction",
      "id": "cdd26ea4829a68c39727404d94a07472",
      "products": [
        {
          "bel": "a(PUBCHEM:5870)",
          "concept": {
            "name": "5870",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "2770521bb78cf3f05f4e73ec06db7d10"
        }
      ],
      "reactants": [
        {
          "bel": "a(PUBCHEM:5757)",
          "concept": {
            "name": "5757",
            "namespace": "PUBCHEM"
          },
          "function": "Abundance",
          "id": "fd3d4b235730b966e67ab14d361be517"
        }
      ]
    },
    {
      "bel": "rxn(reactants(p(HGNC:APP)), products(a(CHEBI:\"amyloid-beta polypeptide 42\"), p(CONSO:\"APP C-terminally truncated carboxyl-terminal fragments\")))",
      "function": "Reaction",
      "id": "afbfb099b5f7773dc4c4cd5e0f56da5f",
      "products": [
        {
          "bel": "a(CHEBI:\"amyloid-beta polypeptide 42\")",
          "concept": {
            "name": "amyloid-beta polypeptide 42",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "ef705fbb8d4e7ba18fb04daf5d329b6b"
        },
        {
          "bel": "p(CONSO:\"APP C-terminally truncated carboxyl-terminal fragments\")",
          "concept": {
            "name": "APP C-terminally truncated carboxyl-terminal fragments",
            "namespace": "CONSO"
          },
          "function": "Protein",
          "id": "e74c619edc3731c06f4ce8315ab08668"
        }
      ],
      "reactants": [
        {
          "bel": "p(HGNC:APP)",
          "concept": {
            "name": "APP",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "d43ae551265c6b6a27038d0b036848cf"
        }
      ]
    }
  ]
}